Share on Pinterest Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Shelby Knowles/Bloomberg/Getty Images Zepbound outperformed ...

Orlando, Fla. — Fracture risk in people treated for obesity appears significantly lower with semaglutide (Wegovy) vs sleeve gastrectomy, new data suggest. Previous animal studies have suggested ...

Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Novo Nordisk ...

Be patient. Wegovy is working behind the scenes, even if physical changes aren’t immediately apparent. It takes time for your body to adjust and for semaglutide to build up to therapeutic levels.

activates two hormone receptors—GLP-1 and GIP—while semaglutide (Wegovy) only targets GLP-1. Both of these hormones help reduce appetite and regulate how your brain responds to food.

Semaglutide's potential in new indications and an amylin-targeting pipeline also gives us confidence in Novo's wide moat. Approved as Wegovy in ... for patients. We convert our fair value estimate ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down FRANKFURT, Germany -- Pharmaceutical company Novo Nordisk A/S, maker of blockbuster ...

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted daily, but keeping up can be a challenge. As an aid ...

They found dark chocolate biscuits triggered the key fullness hormone GLP-1, which is the target of appetite-suppressing injections like Wegovy and Mounjaro. People reported feeling more full ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

Shares had skyrocketed after the introduction of Wegovy and diabetes medicine Ozempic, which are both based on the same basic ingredient, semaglutide. At the peak, the company’s market ...